Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840394 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Eikon Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04840394: Completed Phase 1 study, sponsored by Eikon Therapeutics.
NCT04840394 is a Phase 1 study that has completed, run by Eikon Therapeutics. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04840394, a Phase 1 study, has completed, sponsored by Eikon Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Primary Outcome
Safety and tolerability of BDB018 in monotherapy and in combination with pembrolizumab as measured by the incidence of adverse events and any dose limiting toxicity
Interventions
- DRUG Pembrolizumab
- DRUG BDB018
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 1 |
What the finished NCT04840394 record still lists
NCT04840394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04840394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04840394 about?
NCT04840394 is a clinical study titled "Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors". A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
What is the current status of trial NCT04840394?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-06-22. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT04840394?
The interventions under investigation include: Pembrolizumab (DRUG), BDB018 (DRUG).
Who is sponsoring clinical trial NCT04840394?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04840394's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI